CD86 and Hodgkins lymphoma: Remarkably, the differences in activated B cells (CD19+/CD80+ and CD18+/CD86+) persisted when 14 HIV(+) AHCT recipients with Hodgkin lymphoma were compared directly to HIV(-) AHCT recipients by Wilcoxon rank sum analysis (p<0.0185, Table S3).